Oxpentifylline in Parkinson's disease.
Open Access
- 1 April 1980
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 43 (4) , 360-364
- https://doi.org/10.1136/jnnp.43.4.360
Abstract
The effects of oxpentifylline were assessed in a double-blind trial in 11 patients with Parkinson's disease already under treatment. No significant improvement was noted. Eight patients developed involuntary movements or a worsening of movements if already present. The significance of this unexpected finding is discussed.This publication has 20 references indexed in Scilit:
- DOPAMINERGIC ERGOTS: DRUGS WHICH DISCRIMINATE BETWEEN THE MULTIPLE CLASSES OF DOPAMINE RECEPTORSPublished by Elsevier ,1979
- TIAPRIDE IN PARKINSON'S DISEASEThe Lancet, 1978
- Effects of lisuride and LSD on cerebral monoamine systems and hallucinosisNature, 1978
- Effects of pentoxifylline and theophylline on neurotransmitter uptake and release by synaptosome-rich homogenates of the rat hypothalamusNeuropharmacology, 1977
- Studies with bromocriptineNeurology, 1976
- Effect of some phosphodiesterase inhibitors on central dopamine mechanismsEuropean Journal of Pharmacology, 1976
- Effects of bromocriptine on central dopaminergic receptorsLife Sciences, 1976
- Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects?A reviewPsychopharmacology, 1976
- Dopamine Receptors in the BrainScience, 1975
- EFFECTS OF L-DOPA IN PARKINSON'S DISEASEThe Lancet, 1969